2-(4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy)phenoxy)acetic acid

Name	L-165,041
Synonyms	L-165041 L 1q5041 L-165,041 COMPOUND P 2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]- 4-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPOXY]PHENOXYACETIC ACID 4-[3-(2-PROPYL-3-HYDROXY-4-ACETYL)PHENOXY]PROPYLOXYPHENOXY-ACETIC ACID 2-(4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy)phenoxy)acetic acid Acetic acid, 2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]-
CAS	79558-09-1

Molecular Formula	C22H26O7
Molar Mass	402.44
Density	1.222±0.06 g/cm3(Predicted)
Melting Point	127-128°C(lit.)
Boling Point	600.8±55.0 °C(Predicted)
Solubility	DMSO: >10mg/mL
Appearance	solid
Color	off-white
pKa	3.23±0.10(Predicted)
Storage Condition	2-8°C
Stability	Light Sensitive
MDL	MFCD04974501
In vitro study	L-165041 is a PPARδ agonist, with K i s of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively. L-165041 (1 or 5 µM) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041 negatively affects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10 µM)inhibits PPARδ-independent, VEGF-induced angiogenesis. PPARδ ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10 μM) significantly suppresses S phase transition induced by PDGF.
In vivo study	L-165041 (5 mg/kg/day, i.p.) significantly lowers the formation of lipid droplets in mice. L-165041 markedly reduces the level of both the hepatic cholesterol and triglycerides in mice. L-165041 increases mRNA expression levels of PPARδ compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group.

WGK Germany

Last Update：2024-01-02 23:10:35

biological activity	L-165041 is a cell-penetrating pparδ agonist, ki values for pparδ and PPARγ are 6 nM and about 730 nM, respectively, and can induce adipocyte differentiation in NIH-pparδ cells.
Target	PPAR δ 6 nM (Ki) PPAR γ 730 nM (Ki)
in vitro study	L-165041 is is a PPAR δ agonist, with K I s of 6 nM and appr 730 nM for PPAR δ and PPAR γ, review. L-165041 (1 or 5 µm) traits VEGF-induced endothlial cells (ECs) propagation and migration. L-165041 cellular effects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10 μm), VEGF-induced angiogenesis. PPARδ ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10 μM) significantly suppresses S phase transition induced by PDGF.
in vivo study	L-165041 (5 mg/kg/day, I. p.) the formation of lipid droplets in mice. L-165041 marked mice. L-165041 increases mRNA expression levels of PPARδ compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group.

Last Update：2024-04-10 22:29:15

Product Name: L-165,041 Visit Supplier Webpage Request for quotation
CAS: 79558-09-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Product Name: L-165,041 Visit Supplier Webpage Request for quotation
CAS: 79558-09-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

2-(4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy)phenoxy)acetic acid Request for Quotation